New cancer drug DT-9081 tested in early trial – but study stopped early
Disease control
Terminated
This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.
Phase: PHASE1 • Sponsor: Domain Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC